Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 – Prospective Randomized Placebo-Controlled Double-Blind Trial

Investigators assessed the benefit of adjuvant aspirin in resected PIK3CA-mutated colon cancer patients. Patients with resected colon cancer stage II and III harbouring an activating PIK3CA mutation were included.